ObjectivePhendimetrazine is an amphetamine analogue that acts as a sympathomimetic with anorectic properties, used for weight loss. There is scarce information on the safety of phendimetrazine associated with fetal anomaly when used early in pregnancy. Some studies suggested that use of phendimetrazine during pregnancy may increase the risk of cleft lip and palate, and congenital diaphragmatic hernia. The aim of the study was to evaluate fetal outcomes among pregnant women who were inadvertently exposed to phendimetrazine in early pregnancy. MethodsTotal 62 singleton pregnant women who were inadvertently exposed to phendimetrazine during early pregnancy were prospectively followed up (twin pregnancy was excluded). In addition, 122 age and gravity matched pregnant women were not exposed to any potential teratogenic agent during pregnancy were recruited as controls. ResultsMean age of exposed women was 33.2 ± 4.9 years, with mean gravity was 2.2 ± 1.1 and mean gestational weeks at exposure was 4.2 ± 2.0. All gestations were confirmed by ultrasonography. Of exposed women, 3 (1.0%) had spontaneous abortions, 2 had artifi cial abortion, 23 cases were lost to follow-up and 7 cases were transferred to other hospital. Therefore, 26 pregnancies inadvertently exposed to phendimetrazine were evaluated. Two babies had abnormal outcome: one had choroid plexus cyst, another baby had bilateral equinovarus. In control group, 11 babies were born with abnormal outcome (7.7% vs. 12.0%; P = 0.54; odds ratio, 0.61; 95% confi dence interval, 0.12 to 2.96). ConclusionThese preliminary results suggest that phendimetrazine may not pose substantial fetal risks. Although more information is needed, there is a critical need for further research on medication used during pregnancy.
ObjectiveTo evaluate the difference of serumanti-Müllerian hormone (AMH) levels in women between undergoing previous ovarian surgery with endometriosis and controls. MethodsWe reviewed medical records and evaluated the serum AMH levels of 217 women (26−40 years old) between March 2010 and January 2011, retrospectively. One hundred five patients were previously undergone the ovarian surgery of endometriosis (study group) and 112 women has never undergone ovarian surgery as controls (control group). Exclusion criteria was following factors: irregular menstruation, polycystic ovary syndrome, high BMI (≥30 kg/m 2 ), other endocrine disease. ResultsThe mean age in study group was not different with control group (32.5±3.6 vs. 33.0 ± 3.8 year). The mean serum AMH levels significantly lower in the study group than in control (2.82 ± 2.4 ng/mL vs. 3.82 ± 2.8 ng/mL, P=0.005). When we analyzed the serum AMH levels according to age groups, the patients above 31 years showed significantly lower levels than control (31−35 years, 2.41±1.7 ng/mL vs. 3.84 ± 2.6 ng/mL, P=0.005; 36−40 years, 1.36 ± 2.0 ng/mL vs. 2.68±2.7 ng/mL, P=0.018) The serum AMH levels didn't show any statistical difference in aspect of bilaterality, endometriosis stage, cyst size (≥6 cm). ConclusionWe could consider relatively low serum AMH levels in patients with ovarian endometriosis after surgical treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.